- Home
- GCGR vs CCCC Comparison
GCGR vs CCCC Comparison
Compare GCGR & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GCGR | CCCC |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.3M | 404.7M |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GCGR | CCCC |
|---|---|---|
| Price | $10.10 | $4.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 25.8K | ★ 2.5M |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $10.05 | $1.69 |
| 52 Week High | $10.20 | $5.17 |
Technical Indicators
Market Signals| Indicator | GCGR | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 48.68 | 63.59 |
| Support Level | $10.09 | $3.40 |
| Resistance Level | N/A | $4.60 |
| Average True Range (ATR) | 0.01 | 0.21 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 11.11 | 93.70 |
Price Performance
Historical ComparisonAbout GCGR General Catalyst Global Resilience Merger Corp. Class A Ordinary Shares
General Catalyst Global Resilience Merger Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.